Thermodynamic, Spatial and Methodological Considerations for the Manufacturing of Therapeutic Polymer Nanoparticles.


Journal

Pharmaceutical research
ISSN: 1573-904X
Titre abrégé: Pharm Res
Pays: United States
ID NLM: 8406521

Informations de publication

Date de publication:
24 Feb 2020
Historique:
received: 09 01 2020
accepted: 11 02 2020
entrez: 26 2 2020
pubmed: 26 2 2020
medline: 13 11 2020
Statut: epublish

Résumé

Evaluate fundamental parameters that dictate the effectiveness of drug loading. A model water-soluble drug lacking ionizable groups, pirfenidone (PFD), was encapsulated through nanoprecipitation in poly(ethylene glycol)-poly(lactic acid) (PEG-PLA)-poly(lactic-co-glycolic acid) (PLGA) NPs. Firstly, the thermodynamic parameters predicting drug-polymer miscibility were determined to assess the system's suitability. Then, the encapsulation was evaluated experimentally by two different techniques, bulk and microfluidic (MF) nanoprecipitation. Additionally, the number of molecules that fit in a particle core were calculated and the loading determined experimentally for different core sizes. Lastly, the effect of co-encapsulation of α-lipoic acid (LA), a drug with complementary therapeutic effects and enhanced lipophilicity, was evaluated. The thermodynamic miscibility parameters predicted a good suitability of the selected system. MF manufacturing enhanced the encapsulation efficiency by 60-90% and achieved a 2-fold higher NP cellular uptake. Considering spatial constrictions for drug encapsulation and increasing the size of the PLGA core the number of PFD molecules per NP was raised from under 500 to up to 2000. More so, the co-encapsulation of LA increased the number of drug molecules per particle by 96%, with no interference with the release profile. Thermodynamic, spatial and methodological parameters should be considered to optimize drug encapsulation.

Identifiants

pubmed: 32095934
doi: 10.1007/s11095-020-2783-4
pii: 10.1007/s11095-020-2783-4
pmc: PMC7040083
doi:

Substances chimiques

Antineoplastic Agents 0
Nanocapsules 0
Pyridones 0
monomethoxypolyethyleneglycol-polylactide block copolymer 0
Polylactic Acid-Polyglycolic Acid Copolymer 1SIA8062RS
Lactic Acid 33X04XA5AT
Polyethylene Glycols 3WJQ0SDW1A
pirfenidone D7NLD2JX7U

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

59

Subventions

Organisme : Deutsche Forschungsgemeinschaft (DE)
ID : GO 565/17-3

Références

Soft Matter. 2019 Jan 28;15(4):709-720
pubmed: 30624437
Rev Med Chil. 2014 Dec;142(12):1553-64
pubmed: 25693438
ACS Appl Mater Interfaces. 2015 May 20;7(19):10374-85
pubmed: 25909493
PLoS One. 2013 Aug 05;8(8):e70528
pubmed: 23940587
J Pharm Sci. 2004 Jan;93(1):132-43
pubmed: 14648643
J Am Soc Nephrol. 2009 Aug;20(8):1765-75
pubmed: 19578007
J Am Soc Nephrol. 2011 Jun;22(6):1144-51
pubmed: 21511828
Int J Pharm. 2017 Nov 25;533(1):275-284
pubmed: 28943210
Cancer Chemother Pharmacol. 2004 Feb;53(2):141-50
pubmed: 14564477
Pharm Res. 2009 May;26(5):1025-58
pubmed: 19107579
J Control Release. 1999 Feb 1;57(2):171-85
pubmed: 9971898
FEBS Lett. 1990 Jul 30;268(1):235-7
pubmed: 2384160
Acta Biomater. 2015 Apr;17:193-200
pubmed: 25662913
Expert Rev Clin Pharmacol. 2017 May;10(5):483-491
pubmed: 28266906
Drug Dev Ind Pharm. 1999 Apr;25(4):471-6
pubmed: 10194602
Nat Nanotechnol. 2008 Mar;3(3):145-50
pubmed: 18654486
Nano Lett. 2008 Sep;8(9):2906-12
pubmed: 18656990
Macromolecules. 2011 Sep 27;44(18):7132-7140
pubmed: 22287809
Colloids Surf B Biointerfaces. 2000 Oct 1;18(3-4):301-313
pubmed: 10915952
Small. 2020 Mar;16(9):e1904673
pubmed: 31702878
Drugs. 2015 Feb;75(2):219-30
pubmed: 25604027
J Pharm Sci. 2013 Jul;102(7):2254-63
pubmed: 23649486
Int J Nanomedicine. 2010 Nov 26;5:1057-65
pubmed: 21170353
J Pharm Sci. 1999 Nov;88(11):1182-90
pubmed: 10564068
Clin J Am Soc Nephrol. 2007 Sep;2(5):906-13
pubmed: 17702727
Pharmazie. 2007 Jul;62(7):499-504
pubmed: 17718189
J Pharm Biomed Anal. 2016 Aug 5;127:202-6
pubmed: 27155736
Chem Soc Rev. 2012 Apr 7;41(7):2971-3010
pubmed: 22388185
Int J Pharm. 2004 Nov 22;286(1-2):19-26
pubmed: 15500999
AAPS PharmSciTech. 2004 Mar 08;5(1):E16
pubmed: 15198537
Proc Natl Acad Sci U S A. 2019 May 14;116(20):9831-9836
pubmed: 31036631
Dtsch Med Wochenschr. 2013 Mar;138(11):518-23
pubmed: 23423955
Angew Chem Int Ed Engl. 2014 Oct 20;53(43):11532-7
pubmed: 25196427
Int J Biol Macromol. 2018 Oct 15;118(Pt A):1319-1325
pubmed: 29715556
Int J Pharm. 2019 Sep 10;568:118466
pubmed: 31254623
Pharm Res. 2006 Aug;23(8):1877-87
pubmed: 16850265
Nanotechnology. 2012 Dec 21;23(50):505101
pubmed: 23186914

Auteurs

Sara Maslanka Figueroa (S)

Department of Pharmaceutical Technology, University of Regensburg, Universitaetsstrasse 31, 93053, Regensburg, Germany.

Daniel Fleischmann (D)

Department of Pharmaceutical Technology, University of Regensburg, Universitaetsstrasse 31, 93053, Regensburg, Germany.

Sebastian Beck (S)

Department of Pharmaceutical Technology, University of Regensburg, Universitaetsstrasse 31, 93053, Regensburg, Germany.

Achim Goepferich (A)

Department of Pharmaceutical Technology, University of Regensburg, Universitaetsstrasse 31, 93053, Regensburg, Germany. achim.goepferich@ur.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs
Humans Male Female Health Knowledge, Attitudes, Practice Middle Aged
Vancomycin Polyesters Anti-Bacterial Agents Models, Theoretical Drug Liberation
Humans Melanoma Skin Neoplasms Antineoplastic Combined Chemotherapy Protocols Randomized Controlled Trials as Topic

Classifications MeSH